(415) 353-7070 (appts)
(415) 353-9571 (fax)

Box 1710, UCSF; San Francisco, CA 94143-1710,

additional websites:

UCSF Physician Referral Directory

Harvard College, A.B., 1982, Biochemical Sciences
Stanford University School of Medicine, M.D., 1986, Medicine
University of California, Los Angeles Medical Center, 1996-1987, Internal Medicine
University of Calilfornia, Los Angeles, Residency, 1989, Internal Medicine
University of California San Francisco, Fellowship, 1992, Medical Oncology & Hematology

2005 - Present:

Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, and Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol. Progress 2005, 21 (1), 205 -220.

Nellis DF, Giardina SL, Janini G, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, and Kirpotin DB. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 2. Conjugate micelle identity, purity, stability and potency analysis. Biotechnol. Progress 2005, 21 (1), 221 -232.

Melisko ME, Kunwar S, Prados M, Berger MS, and Park JW. Brain metastases of breast cancer. Expert Rev. Anticancer Ther. 2005, 5(2):253-68.

Campbell MJ, Scott J, Maecker H, Park JW, and Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res. Treat. 2005, 91(2):163-71.

Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Park JW, Kirpotin DB, and Benz CC. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res. 2005, 11(9):3392-401.

Horv‡th G, Mikl—s Petr‡s M, Szentesi G, F‡bi‡n A, Park JW, Vereb G, and Szšllsi J. Selecting optimal fluorophores and flow cytometer for fluorescence resonance energy transfer measurements. Cytometry A 2005, 65(2):148-57.

Mocanu MM, Fazekas Z, Petr‡s M, Nagy P, SebestyŽn Z, Isola J, T’m‡r J, Park JW, Vereb G, and Szšllsi J. Associations of ErbB2, 1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett. 2005, 227(2): 201-212.

Nagy P, Bene L, Hyun WC, Vereb G, Braun M, Antz C, S‡ndor Damjanovich S, Paysan J, Park JW, and Szšllsi J. Novel calibration method for flow cytometric fluorescence resonance energy transfer measurements between visible fluorescent proteins. Cytometry 2005, 67(2):86-96.

Li K-L, Wilmes, LJ, Henry RG, Maria G. Pallavicini, Park JW, Hu-Lowe DD, McShane TM, Shalinsky, DR, Fu Y-J, Brasch RC, and Hylton NM. Heterogeneity in angiogenic response of BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J. Magn. Resonance Imaging (JMRI) 2005, 22:511-519.

Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, and Bankiewicz KS. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurology 2005, 196:381-9.

Krauze MT, Tracy R. McKnight TR, Yamashita Y, Bringas J, Noble C, Saito R, Geletneky K, Forsayeth J, Park JW, Mitchel S. Berger MS and Bankiewicz KS. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc. 2005, 16(1-3):20-6.

Krauze MT, Saito R, Noble CO, Tamas M, Bringas JR, Park JW, Berger MS, and Bankiewicz KS. Reflux-free cannula for convection-enhanced delivery permitting high-speed delivery of therapeutic agents. J. Neurosurg. 2005, 103(5):923-9.

Krauze MT, Saito R, Noble CO, Bringas JR, McKnight TR, Park JW, and Bankiewicz KS. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp. Neurology 2005, Nov;196(1):104-11.

Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee Jr FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD and Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol. 2005, 23(24):5464-73.

Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo J and Wilding G. Phase I trial of the oral anti-angiogenesis agent AG-013736, in patients with advanced solid tumors Ð pharmacokinetic and clinical results. J. Clin. Oncol. 2005, 23(24):5474-83.

Mamot C, Drummond DC, Noble CO, Guo Z, Hong K, Kirpotin DB, and Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs. Cancer Res. 2005, 65(24):11631-8.

Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Kirpotin DB, Bankiewicz KS and Park JW. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006, 66: 2801-2806.

Drummond D, Noble CO, Guo Z, Hong K, Park JW, and Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006, 66: 3271-3277.

Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO IV, Park JW, Marks JD, Benz CC, and Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Therapy 2005, Dec 8; [Epub ahead of print].

Saito R, Noble CO, Krauze M, Tamas, M, Drummond DC, Kirpotin DB, Hong K, Park JW, Berger MS, and Bankiewicz KS. Tissue affinity of the infusate affects the volume of distribution during convection enhanced delivery into rodent brains; implications for local drug delivery. J. Neurosci. Methods 2006, Feb 9; [Epub ahead of print].

Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta 2006, Apr 17; [Epub ahead of print].

Hadaczek P, Mirek H, Tamas L, Bohn M, Noble C, Park JW, and Bankiewicz KS. Perivascular pump driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Molecular Therapy 2006, Apr 28; [Epub ahead of print].

Kirpotin DB, Drummond DC, Hong K, Shao Y, Shalaby R, Nielsen UB, Marks JD, Benz CC, and Park JW. Antibody targeting of long circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66(13): 6732-40.

Marx C, Berger C, Fan XF, Amend C, Johnson J, Scott G, Hann B, Park JW, and Benz CC. Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Develop. Technol. 2006, 4(3): 273-84.

Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, and Bankiewicz KS. Convection-enhanced delivery of nanoliposomal topotecan enables an effective continuous low-dose chemotherapy against malignant glioma xenograft models. Neuro-Oncology 2006 Jul;8(3):205-14.

Yamashita Y, Saito R, Krauze M, Kawaguchi T, Noble CO, Drummond DC, Kirpotin DB, Pieper RO, Park JW, Berger MS and Bankiewicz KS. Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts. Targeted Oncology 2006, in press.

Krauze MT, Forsayeth J, Park JW, and Bankiewicz KS. Real-time imaging and quantification of brain delivery of liposomes. Pharm. Res. 2006 Nov;23(11):2493-504. Epub 2006 Sep 14.

Mamot C, Ritschard R, KŸng W, Reuter J, Park JW, Herrmann R and Rochlitz CF. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Targeting 2006;14(4):215-23.

Hayes ME, Drummond DC, Hong K. Zheng WW, Khorosheva VA, Cohen JA, Noble CO IV, Park JW, Marks JD, Benz CC, and Kirpotin DB, Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Molec. Pharmacol. 2006, 3(6):726-36.

Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW and Bankiewicz KS. Convection-enhanced delivery of nanoliposomal CPT-11 (Irinotecan) and pegylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-Oncology 2007, Jan;9(1):20-8.

Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, and Small EJ. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU International 2007, 99 (3), 519Ð524.

Marx C, Yao C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, and Benz CC. Proteosome regulated ErbB2 and estrogen receptor pathways in breast cancer. Mol. Pharm. 2007, in press.

Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, and Sims R. Treatment with autologous antigen presenting cells activated with HER2-based antigen (lapuleucel-T): results of a Phase 1 study and immunologic and clinical activity in HER2-overexpressing breast cancer. J. Clin. Oncol. 2007, 25(24):3680-7.

7/22/08